Company / Free Cash Flow per Share
Taysha Gene Therapies, Inc. Free Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.46
FY2025
5-year range
-$3.52 / -$0.41
FY2021-FY2025
Trend
-11.3%
vs FY2024
Sector context
#85 of 192
Health Care
What the data says
At $-0.46, Taysha Gene Therapies, Inc.'s free cash flow per share ranks #85 of 192 in the Health Care sector. Improved from $-1.72 to $-0.46 over the past 2 years.
Based on SEC 10-K filings.
-0.46 in FY2025.
Improved from $-1.72 to $-0.46 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#85 of 192 in Health CareTop 44% of 192This company -$0.46 Sector average -$19.84
▼
+97.7% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 11.3% year-over-year.
- Ranks #85 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2024.
- Lowest free cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.46 | -11.3% |
| FY2024 | -$0.41 | +76.2% |
| FY2023 | -$1.72 | +49.9% |
| FY2022 | -$3.44 | +2.1% |
| FY2021 | -$3.52 | -101.5% |
| FY2020 | -$1.74 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026